Related Experiment Videos
Endoscopic pneumatic balloon dilatation for achalasia of the cardia
1Specialists Centre, Penang.
Insights
Endoscopic pneumatic balloon dilation is a safe and effective initial treatment for achalasia of the cardia. This study showed a 93% success rate, with most patients avoiding further treatment or surgery.
Area of Science:
- Gastroenterology
- Endoscopy
- Digestive Diseases
Background:
- Achalasia of the cardia is a primary esophageal motility disorder.
- Current treatments include surgery, botulinum toxin injection, and pneumatic dilatation.
- The optimal initial management strategy for achalasia remains debated.
Purpose of the Study:
- To evaluate the efficacy and safety of endoscopic pneumatic balloon dilatation as the initial treatment for achalasia of the cardia.
- To assess the long-term outcomes and complication rates associated with this procedure.
Main Methods:
- A retrospective study of 15 patients with achalasia.
- Patients underwent pneumatic balloon dilatation using a polyethylene dilator (Microvasive Rigiflex Balloon Dilator).
- A total of 19 dilatations were performed over a 6-year period, with a mean follow-up of 31.5 months.
Main Results:
- An overall treatment success rate of 93% was achieved.
- 11 patients (73.3%) did not require further dilatation.
- 3 patients (20%) required 1-2 additional dilatations; only 1 patient needed elective surgery.
Conclusions:
- Endoscopic pneumatic balloon dilation is a safe and effective initial treatment for achalasia.
- It offers a high success rate and low complication rate, making it a viable first-line option.
- This minimally invasive approach should be considered the initial treatment of choice for most achalasia patients.
Abstract:
This study evaluated the efficacy and safety of endoscopic pneumatic balloon dilatation as the initial treatment for achalasia of the cardia. 15 patients with achalasia underwent a total of 19 dilatations using the new polyethylene dilator (Microvasive Rigiflex Balloon Dilator) over the last 6 years. An overall treatment success rate of 93% was achieved. 11 patients (73.3%) have not required a further dilatation and 3 patients (20%) required between 1 and 2 further dilatations. Elective surgery was necessary in 1 patient. The mean follow-up period was 31.5 months. There was no complication or death attributable to the procedure. Endoscopic pneumatic balloon dilation is a safe and effective treatment for achalasia and should be considered as the initial treatment of choice in most patients with achalasia.